Literature DB >> 16363320

A new practical technique to reduce allogeneic blood exposure and hospital costs while preserving clotting factors after cardiopulmonary bypass: the Hemobag.

Keith A Samolyk1, Scott R Beckmann, Randall C Bissinger.   

Abstract

Recent data independently linking allogeneic blood use to increased morbidity and mortality after cardiopulmonary bypass (CPB) warrants the study of new methods to employ unique and familiar technology to reduce allogeneic blood exposure. The Hemobag allows the open-heart team to concentrate residual CPB circuit contents and return a high volume of autologous clotting factors and blood cells to the patient. Fifty patients from all candidates were arbitrarily selected to receive the Hemobag (HB) therapy. A retrospective control group of 50 non-Hemobag (NHB) patients were matched to the HB group patient-by-patient for comparison according to surgeon, type of procedure, age, body surface area (BSA), body weight and CPB time. Many efforts to conserve blood (Cell Saver and ANH) were employed in both groups. Post-CPB cell washing of circuit contents was additionally employed in the control group. There were no significant differences between the HB and NHB groups in regard to patient morphology, pre-op cell concentrations, distribution of surgeon or procedures (41% valve, 16% valve/coronary artery bypass graft (CABG), balance CABG), pump and ischemic times and Bayes National Risk scores. The average volume returned to the patient from the HB was 817+/-198 mL (1 SD). Average processing time was 11 min. The Hemobag contained an average platelet count of 230+/-80 K/mm3, fibrinogen concentration of 413 +/- 171 mg/dl, total protein of 8.0+/-2.8 gm/dl, albumin of 4.4+/-1.2 gm/dl and hematocrit of 43+/-7%. Factor VII, IX and X levels in three HB contents averaged 259% greater than baseline. Substantial reductions were achieved in both allogeneic blood product avoidance and cost to the hospital with use of the HB. Infusion of the Hemobag concentrate appears to recover safely substantial proteins, clotting factor and cell concentration for all types of cardiac procedures, maintaining the security of a primed circuit.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16363320     DOI: 10.1191/0267659105pf831oa

Source DB:  PubMed          Journal:  Perfusion        ISSN: 0267-6591            Impact factor:   1.972


  8 in total

1.  Changes in mechanical fragility and free hemoglobin levels after processing salvaged cardiopulmonary bypass circuit blood with a modified ultrafiltration device.

Authors:  Sarah K Harm; Jonathan H Waters; Pamela Lynn; Robert Dyga; Jay S Raval; Ross F DiMarco; Mark H Yazer
Journal:  J Extra Corpor Technol       Date:  2012-03

2.  An in-vitro comparison between Hemobag and non-Hemobag ultrafiltration methods of salvaging circuit blood following cardiopulmonary bypass.

Authors:  Ed Delaney; David Rosinski; Harvey Ellis; Keith A Samolyk; Jeffrey B Riley
Journal:  J Extra Corpor Technol       Date:  2010-06

3.  Improved coagulation and blood conservation in the golden hours after cardiopulmonary bypass.

Authors:  Scott R Beckmann; Dee Carlile; Randall C Bissinger; M Burrell; Thomas Winkler; William W Shely
Journal:  J Extra Corpor Technol       Date:  2007-06

4.  Use of the Hemobag for modified ultrafiltration in a Jehovah's Witness patient undergoing cardiac surgery.

Authors:  David M Moskowitz; James J Klein; Aryeh Shander; Seth I Perelman; Kirk A McMurtry; Katherine M Cousineau; M Arisan Ergin
Journal:  J Extra Corpor Technol       Date:  2006-09

5.  On-line autotransfusion waste calculator.

Authors:  Jeffrey B Riley; Keith A Samolyk
Journal:  J Extra Corpor Technol       Date:  2008-03

6.  Increased accuracy in heparin and protamine administration decreases bleeding: a pilot study.

Authors:  Marx Runge; Christian H Møller; Daniel A Steinbrüchel
Journal:  J Extra Corpor Technol       Date:  2009-03

7.  A novel autotransfusion device saving erythrocytes and platelets used in a 72 h survival swine model of surgically induced controlled blood loss.

Authors:  Kévin Schreiber; Benoit Decouture; Audrey Lafragette; Stéphane Chollet; Marine Bruneau; Maxence Nicollet; Catherine Wittmann; Francis Gadrat; Alexandre Mansour; Patricia Forest-Villegas; Olivier Gauthier; Gwenola Touzot-Jourde
Journal:  PLoS One       Date:  2022-03-24       Impact factor: 3.240

8.  The Hemobag: the modern ultrafiltration system for patients undergoing cardiopulmonary by pass.

Authors:  Andrea Colli; Sara Balduzzi; Xavier Ruyra
Journal:  J Cardiothorac Surg       Date:  2012-06-14       Impact factor: 1.637

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.